Introduction {#Sec1}
============

With its rich cultural heritage and biodiversity, traditional Chinese medicine (TCM) has potential as a source for the discovery of structurally novel bioactive compounds. During the last twenty years, considerable efforts have been dedicated towards the exploration of the natural product chemistry of TCM. *Homalomena occulta* (Lour.) was officially listed in the Chinese Pharmacopoeia (named Qian-nian-jian) \[[@CR1]\], and was found to occur in the tropical and sub-tropical areas of Asia and America. The plant has been used for the treatment of rheumatoid arthritis, trengthening tendons and bones, and invigorating the kidney and liver \[[@CR2], [@CR3]\]. Recent reports of *H. occulta* have also shown that the species is one of the most prolific sources of compounds with new structures \[[@CR2]--[@CR6]\].

Our research group has considerably focused on phytochemical investigations of TCM \[[@CR7]--[@CR10]\]. As part of our continuing efforts to obtain novel compounds with exquisite structural architectures, we initiated a chemical investigation of *H. occulta*, which has thus far led to the isolation and structural elucidation of six oplopanane sesquiterpenoids (**1**--**6**), including four new (**1**--**4**) and one 3,5-*seco*-oplopanane (**6**), together with three previously reported sesquiterpenoids (**7**−**9**).

Results and Discussion {#Sec2}
======================

By means of diverse chromatographic methods, including silica gel and LH-20, four new oplopanane sesquiterpenoids (**1**−**4**) (Fig. [1](#Fig1){ref-type="fig"}) have been purified from an 88 % ethanol/water extract of the rhizomes of *H. occulta*.Fig. 1Molecular structures of sesquiterpenoids **1**−**9**

Compound **1** was isolated as an optically active colorless oil with $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ --54 (*c* 0.07, CHCl~3~). Its molecular formula was analyzed as same as oplopanone (**5**) \[[@CR11]\], i.e. C~15~H~26~O~2~, based on a pseudomolecular ion peak at *m*/*z* 256.2272 \[M + NH~4~\]^+^ (calcd. 256.2271) in the positive HRESIMS spectrum, indicating three degrees of unsaturation. The IR absorptions suggested the existence of hydroxy (3382 cm^−1^) and ketone (1705 cm^−1^) functionalities. The ^13^C NMR spectra (Table [1](#Tab1){ref-type="table"}) showed the presence of one oxygenated quaternary carbon (*δ*~C~ 73.2) and one ketone carbon (*δ*~C~ 212.3). Overall NMR pattern, together with the established molecular formula, showed close resemblance to those of oplopanone (**5**) \[[@CR11]\], which indicated that compounds **1** and **5** were possibly epimers of each other. The large coupling constants of *J*~H-1,H-6~ (12.0 Hz) and *J*~H-5,H-6~ (10.4 Hz) indicated the *trans* relationship from H-1 to H-6, and from H-5 to H-6, while the small coupling constants of *J*~H-6,H-7~ (4.0 Hz) suggested H-7 as *β*-oriented. A molecular modeling study based on no NOE correlation from H-1 to H~3~-14 was used to determine the *β*-oriented Me-14. Finally, compound **1** was 6-*epi*-oplopanone.Table 1NMR spectroscopic data for compound **1** in CDCl~3~Position*δ* ~H~ (*J* in Hz)*δ* ~C~Position*δ* ~H~ (*J* in Hz)*δ* ~C~**1**2.07, ddd (6.8, 12.0, 12.0)52.5 (d)**8a**\
**8b**1.55, m\
1.01, dd (3.2, 13.6)23.0 (t)**2a**1.90, m24.7 (t)**9a**1.77, dt (3.2, 12.4)42.2 (t)**2b**1.42, m**9b**1.40, m**3a**1.94, dt (2.8, 6.0)27.5 (t)**10**73.2 (s)**3b**1.58, m**4**212.3 (s)**11**1.67, m29.2 (d)**5**3.12, ddd (3.2, 10.4, 10.4)50.5 (d)**12 and 13**0.78, d (7.2)\
0.88, d (7.2)15.8 (q)\
21.3 (q)**6**1.35, ddd (4.0, 10.4, 12.0)49.1 (d)**14**1.09, s19.4 (q)**7**1.59, m42.7 (d)**15**2.15, s31.5 (q)

Compound **2**, obtained as an optically active colorless oil with $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ +20 (*c* 0.1, CHCl~3~), was assigned a molecular formula C~15~H~26~O~3~ as analyzed from a pseudomolecular ion at *m*/*z* 277.1779 \[M + Na\]^+^ (calcd. 277.1774) in its positive HRESIMS, indicative of three degrees of unsaturation. Its IR spectrum showed absorptions for hydroxy (3392 cm^−1^) and ketone (1704 cm^−1^) groups. A spectroscopic analogy of **2** with **1** indicated that compound **2** was an oplopanane-type sesquiterpenoid. The significant variations of **1** and **2** in their ^1^H NMR spectra were the disappearance of methylene signals of H~2~-2 (*δ*~H~ 1.90/1.42) in **1** and the appearance of a multiplet at *δ*~H~ 4.10 in **2**. These changes could be explained by the presence of a hydroxy group at C-2 in compound **2**, which was further elucidated from an HMBC experiment. In confirmation of the relative configuration, **2** gave a 2-monoacetate (**2a**) (Table [2](#Tab2){ref-type="table"}) after overnight treatment with Ac~2~O/Py (Sect. [3](#Sec3){ref-type="sec"}). As in **2a**, the coupling constants *J*~1,6~ = 12.4 Hz, *J*~1,2~ = 9.2 Hz, *J*~5,6~ = 2.4 Hz, and *J*~6,7~ = 8.9 Hz allowed the placement of H-5, H-6, and H-7 on *α*-orientation, and H-1 and OH-2 on *α*-orientation. The NOE correlations of H~3~-14 with H-2/H-6, and H-5 with H-2/H-7 were used to determine H~3~-14 as *β*-oriented. Thus, the structure of **2** was established as 5,7-*diepi*-2*α*-hydroxyoplopanone.Table 2NMR spectroscopic data for compounds **2**, **2a**, and **3** in CDCl~3~Position**22a3***δ* ~H~ (*J* in Hz)*δ* ~C~*δ* ~H~ (*J* in Hz)*δ* ~C~*δ* ~H~ (*J* in Hz)*δ* ~C~**1**1.50, m60.4 (d)1.75, dd (9.2, 12.4)59.9 (d)1.42, dt (4.8, 11.6)57.5 (d)**2a**4.10, m72.2 (d)5.08, ddd (5.6, 8.8, 9.2)74.0 (d)1.78, dt (4.8, 12.4)25.4 (t)**2b**1.18, m**3a**1.82, m36.9 (t)2.08, m35.8 (t)1.75, m22.5 (t)**3b**1.82, m1.93, m1.58, m**4**210.9 (s)210.0 (s)3.98, q (6.4)68.6 (d)**5**1.75, m42.2 (d)2.79, ddd (2.4, 8.0, 10.0)44.1 (d)1.72, m48.9 (d)**6**2.73, m52.6 (d)1.86, ddd (2.4, 8.9, 12.4)53.2 (d)1.33, m44.6 (d)**7**1.03, m49.5 (d)1.15, m49.7 (d)1.18, m50.1 (d)**8a**1.51, m22.61.58, m22.31.62, m23.1**8b**1.51, m(t)1.11, m(t)1.07, m(t)**9a**1.34, m41.5 (t)1.77, m41.0 (t)1.73, m41.8 (t)**9b**1.34, m1.38, m1.37, m**10**73.4 (s)72.0 (s)73.0 (s)**11**1.30, m28.7 (d)1.38, m29.0 (d)1.91, m28.1 (d)**12 and 13**0.61, d (6.8)\
0.83, d (6.8)21.7 (q)0.66, d (6.8)21.9 (q)0.89, d (8.4)\
0.93, d (7.2)15.6 (q)15.4 (q)0.89, d (6.8)15.4 (q)21.8 (q)**14**1.21, s20.5 (q)1.26, s21.0 (q)1.17, s20.1 (q)**15**2.15, s29.8 (q)2.20, s30.1 (q)1.18, d (6.4)23.1 (q)**C=O**171.3 (s)**Me**2.04, s21.3 (q)

Compounds **3** and **4**, both isolated as optically active white floc with $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ −17 (*c* 0.1, CHCl~3~) and $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ −27 (*c* 0.1, CHCl~3~), respectively, possessed the same molecular formula of C~15~H~28~O~2~ based on the positive HRESIMS data at *m*/*z* 258.2422 and 258.2428, respectively (\[M + NH~4~\]^+^, calcd. 258.2428). Their IR peaks at 3398 and 3352 cm^−1^ suggested the presence of hydroxy groups. Their ^13^C NMR spectra were similar to those of **1**, with the exception that the carbonyl carbon at *δ*~C~ 212.3 in **1** was replaced by hydroxy-bearing methine carbons at *δ*~C~ 68.6 and 69.7 in **3** and **4**, respectively. The replacements of the C-4 ketone by secondary hydroxy group were supported by the presence of a quartet at *δ*~H~ 3.98 (1H, *J* = 6.4 Hz, assigned to H-4) of **3** and a doublet of quartet at *δ*~H~ 4.00 (1H, *J* = 4.0, 6.4 Hz, assigned to H-4) for **4** in the ^1^H NMR spectrum, which were confirmed from HMBC correlations from H-4 to C-3, C-5, C-6, and C-15. The structures of **3** and **4** were thus deduced as epimers of 4,10-dihydroxyoplopanane. The relative configurations of **3** and **4** were finalized by comparing their spectroscopic features with those of **1** and NOE experiment. The large coupling constants of *J*~1,6~ = 11.6 Hz in **3**/**4** and **3a**/**4a** (acetate of **3**/**4**, Sect. [3](#Sec3){ref-type="sec"} and Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}) were used to assign H-1 and H-6 as *α*- and *β*-orientation, respectively. Irradiation of H-4 enhanced signals for H-6 and H-11 in **3a** (acetate of **3**) and **4** allowed H-5 and H-7 as *α*-orientated. Efforts on the determination of the absolute configurations at C-4 in compounds **3** and **4** by using Mosher method failed. Therefore the structures of **3** and **4** were elucidated as depicted and named oplopananol and 4-*epi*-oplopananol, respectively.Table 3NMR spectroscopic data for compounds **3a**, **4**, and **4a** in CDCl~3~Position**3a44a***δ* ~H~ (*J* in Hz)*δ* ~C~*δ* ~H~ (*J* in Hz)*δ* ~C~*δ* ~H~ (*J* in Hz)*δ* ~C~**1**1.38, m57.6 (d)1.44, dt (4.0, 12.8)57.9 (d)1.43, dt (4.8, 11.6)57.7 (d)**2a**1.70, m25.4 (t)1.77, m26.0 (t)1.74, m26.0 (t)**2b**1.20, m1.08, m1.74, m**3a**1.86, m24.4 (t)1.80, m23.6 (t)1.80, m24.2 (t)**3b**1.55, m1.13, m1.53, m**4**4.98, q (6.4)73.1 (d)4.00, dq (4.0, 6.4)69.7 (d)5.06, m72.7 (d)**5**1.38, m46.9 (d)2.05, m48.7 (d)2.12, m45.2 (d)**6**1.14, m45.1 (d)0.93, m46.2 (d)0.98, m45.9 (d)**7**1.22, m50.0 (d)1.21, m50.1 (d)1.18, m49.9 (d)**8a**1.59, m23.3 (t)1.63, ddt (3.2, 4.0, 13.6)23.4 (t)1.63, dq (4.0, 13.6)23.2 (t)**8b**1.03, dt (3.6, 11.6)1.06, m1.08, m**9a**1.76, dt (3.6, 12.4)41.9 (t)1.76, m41.9 (t)1.77, m41.9 (t)**9b**1.35, m1.37, dt (4.0, 13.2)1.36, dt (4.0, 12.8)**10**73.0 (s)73.0 (s)73.0 (s)**11**1.86, m28.2 (d)1.93, m (2.4)28.5 (d)2.09, m28.1 (d)**12 and 13**0.72, d (7.2)\
0.90, d (6.8)22.0 (q)0.72, d (6.8)\
0.94, d (6.8)15.7 (q)0.75, d (6.8)\
0.94, d (6.8)15.7 (q)15.5 (q)21.9 (q)22.0 (q)**14**1.12, s19.9 (q)1.14, s20.1 (q)1.14, s20.1 (q)**15**1.19, d (6.4)19.6 (q)1.12, d (6.4)17.0 (q)1.16, d (6.4)13.8 (q)**16**170.9 (s)170.6 (s)**17**2.01, s21.3 (q)2.01, s21.5 (q)

On the basis of NMR, MS, optical rotation data and comparison with literature values, the known sesquiterpenoids were elucidated as oplopanone (**5**) \[[@CR11]\], taiwaninone A (**6**) \[[@CR12]\], T-muurolol (**7**) \[[@CR13]\], *α*-cadinol (**8**) \[[@CR14]\], and clovane-2*β*,9*α*-diol (**9**) \[[@CR15]\]. Naturally occurring oplopanane sesquiterpenoids are rarely reported \[[@CR16], [@CR17]\]. Literature searching showed that there were no more than 20 such type sesquiterpenoids reported up to now, distributed among the families of Alismataceae \[[@CR16], [@CR17]\], Araliaceae \[[@CR18]\], Araceae \[[@CR19]\], Asteraceae \[[@CR20]\], Chloranthaceae \[[@CR21]\], Cyperaceae \[[@CR22]\], Magnoliaceae \[[@CR23]\], Meliaceae \[[@CR24]\], Schisandraceae \[[@CR25]\], Salicaceae \[[@CR26]\], and Zingiberaceae \[[@CR27]\]. In this study, six oplopananes (**1**--**6**), including four new (**1**--**4**) and one 3,5-*seco*-oplopanane (**6**), were discovered from the rhizomes of *H. occulta*. In addition three new oplopananes (**2a**--**4a**) were also obtained by chemical transformation. These results indicated that *H. occulta* was a rich source of novel natural products.

Experimental Section {#Sec3}
====================

General {#Sec4}
-------

Optical rotations were recorded on a 241 polarimeter (Perkin-Elmer). Infrared (IR) spectra were obtained with a FTS 165-IR instrument (Bio-Rad, USA). NMR spectra were acquired on a Varian INOVA-400 FT-NMR spectrometer (USA). HRESIMS were measured on a Bruker APEX II spectrometer. Sephadex LH-20 (Amersham Biosciences) and silica gel (200**--**300 mesh, Qingdao Haiyang Chemical Co., Ltd) were used for column chromatography (CC), whereas TLC analyses were carried out with glass plates pre-coated with silica gel and the spots were visualized by spraying with 98 % H~2~SO~4~/EtOH in (5/95, v/v) followed by heating. All solvents used were analytical grade.

Plant Materials {#Sec5}
---------------

The rhizomes of *H. occulta* Lours (Araceae), collected from Guangxi in China, were purchased from Lanzhou Fuxinghou Herbal Medicines Ltd. Co. in February 2007. The materials were identified by Dr. Huan-Yang Qi at Lanzhou Institute of Chemical Physics (LICP), and a voucher specimen (ZY2007H001) was deposited at the herbarium of LICP.

Extraction and Isolation {#Sec6}
------------------------

The air-dried rhizomes (13.0 kg) of *H. occulta* were powdered and extracted with 88 % ethanol/water (v/v) at 60 °C (12 h × 3). After dried in vacuum, the residue (410 g) was suspended in water (1.5 L) and applied to a liquid--liquid partitioning against petroleum ether (PE), EtOAc, and *n*-BuOH (each 1.0 L × 3) continuously. The dried PE part (257 g) was chromatographed over silica gel (1.5 kg), using gradient PE/acetone (v/v, from 80:1 to 1:1, each about 8.0 L) to yield eleven fractions (A1--A11). Fraction A2 (55 g) was subjected to silica gel CC eluting with CHCl~3~/PE gradient system to afford compound **8** (18.2 mg). Fraction A3 (21 g) was purified over silica gel with PE/CHCl~3~ (v/v, 1:1) to afford **7** (4.5 mg). Fraction A5 (34 g) was fractionated consecutively over silica gel and Sephadex LH-20 (CHCl~3~/MeOH, 1:1, v/v) to yield compound **5** (4.5 mg). Fraction A6 (12 g) was chromatographed on a silica gel column eluting with PE/acetone (v/v, 10:1, 8:1, 5:1, 3:1, and 1:1) to afford compound **1** (5.1 mg). Fraction A7 (15 g) was fractionated consecutively over silica gel with PE/acetone (8:1) and Sephadex LH-20 (CHCl~3~/MeOH, 1:1, v/v) to yield **2** (7.8 mg), **3** (23.1 mg), **4** (17.7 mg), **6** (17.8 mg), and **9** (2.1 mg).

### 7-*Epi*-oplopanone (**1**) {#Sec7}

Colorless oil; $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$--54 (*c* 0.07, CHCl~3~); IR (neat) *v*~max~ 3382, 2926, 2857, 1705, 1458, 1383, 1119, 1094, 1027 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [1](#Tab1){ref-type="table"}); HRESIMS *m*/*z* \[M + NH~4~\]^+^ 256.2272 (calcd for C~15~H~30~O~2~N, 256.2271).

### 5,7-*Diepi*-2*α*-hydroxyoplopanone (**2**) {#Sec8}

Colorless oil; $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ +20 (*c* 0.1, CHCl~3~); IR (neat) *v*~max~ 3392, 2955, 2935, 2871, 1704, 1460, 1380, 1365, 1173, 1121, 1049 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [2](#Tab2){ref-type="table"}); HRESIMS *m*/*z* \[M + Na\]^+^ 277.1779 (calcd for C~15~H~26~O~3~Na, 277.1774).

### Oplopananol (**3**) {#Sec9}

White floc; $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$--17 (*c* 0.1, CHCl~3~); IR (neat) *v*~max~ 3398, 2959, 2933, 1461, 1370, 1129 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [2](#Tab2){ref-type="table"}); HRESIMS *m*/*z* \[M + NH~4~\]^+^ 258.2422 (calcd for C~15~H~32~O~2~N, 258.2428).

### 4-*Epi*-oplopananol (**4**) {#Sec10}

White floc; $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ --27 (*c* 0.1, CHCl~3~); IR (neat) *v*~max~ 3352, 2956, 2924, 2856, 1571, 1458, 1421, 1365, 1128, 1062, 944 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [3](#Tab3){ref-type="table"}); HRESIMS *m*/*z* \[M + NH~4~\]^+^ 258.2428 (calcd for C~15~H~32~O~2~N, 258.2428).

Acetylation of **2** to **4** {#Sec11}
-----------------------------

A solution of compounds in a mixture of acetic anhydride--pyridine (1:1) were stirred fully and settled at 25 °C for 12 h. After concentration and storage in *vacuo* compounds **2a**, **3a**, and **4a** were obtained and identified.

### 5,7-*Diepi*-2*α*-acetoxyoplopanone (**2a**) {#Sec12}

Colorless oil; $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ +7 (*c* 0.2, CHCl~3~); IR (neat) *v*~max~ 3449, 2934, 2871, 1734, 1712, 1370, 1247, 1044, 968 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [2](#Tab2){ref-type="table"}); HRESIMS *m*/*z* \[M + Na\]^+^ 319.1883 (calcd for C~17~H~28~O~4~Na, 319.1880).

### 4-Acetoxyoplopananol (**3a**) {#Sec13}

Colorless oil; $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$--41 (*c* 0.2, CHCl~3~); UV (CHCl~3~) *λ*~max~(log ε) 246 (1.56) nm; IR (neat) *v*~max~ 3423, 2960, 2935, 2892, 1736, 1458, 1375, 1247, 1134, 1033, 930 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [3](#Tab3){ref-type="table"}); HRESIMS *m*/*z* \[M + Na\]^+^ 305.2091 (calcd for C~17~H~30~O~3~Na, 305.2087).

### 4-*Epi*-acetoxyoplopananol (**4a**) {#Sec14}

White floc; $\documentclass[12pt]{minimal}
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                \begin{document}$$[\alpha ]_{D}^{20}$$\end{document}$ --10 (*c* 0.2, CHCl~3~); UV (CHCl~3~) *λ*~max~(log ε) 246 (1.48) nm; IR (neat) *v*~max~ 3420, 2858, 2935, 2872, 1732, 1374, 1248, 1126, 1035, 953 cm^−1^; ^1^H NMR (CDCl~3~, 400 MHz) and ^13^C NMR (CDCl~3~, 100 MHz) (Table [3](#Tab3){ref-type="table"}); HRESIMS *m*/*z* \[M + Na\]^+^ 305.2093 (calcd for C~17~H~30~O~3~Na, 305.2087).
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